The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $20,987,624 in first-year total cost, median $918,238.
Most frequent study sections
- Special Emphasis Panel[ZAI1 AWA-M (J2)]5
- Special Emphasis Panel[ZAI1 JRR-M (J4)]5
- Special Emphasis Panel[ZAI1 RCU-M (J1)]5
- Special Emphasis Panel[ZAI1 AWA-M (J1)]3
- Special Emphasis Panel[ZAI1 JRR-M (J3)]1
Most frequent institutions
- BIOMEDICAL RESEARCH INSTIT/ SOUTHERN, CA1
- CATHOLIC UNIVERSITY OF AMERICA1
- EMORY UNIVERSITY1
- ETUBICS CORPORATION1
- GENEVA FOUNDATION1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for Biodefense1R01AI111539-01 | BURNS, CHRISTOPHER JOHNXERRI, LUIGI | VENATORX PHARMACEUTICALS, INC., PA | $1,738,775 | ZAI1 |
| 2014 | Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&Toxoplasmosis1R01AI111341-01 | VAN VOORHIS, WESLEY C | UNIVERSITY OF WASHINGTON, WA | $1,580,174 | ZAI1 |
| 2014 | Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb1R01AI111397-01 | ALLAND, DAVID | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $1,549,810 | ZAI1 |
| 2014 | Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC11R01AI111464-01 | CHENG, XIAODONGWALKER, DAVID H | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $1,538,676 | ZAI1 |
| 2014 | Development of a Universal Influenza Vaccine1R01AI111364-01 | JONES, FRANK R.PAESSLER, SLOBODAN | ETUBICS CORPORATION, WA | $1,398,670 | ZAI1 |
| 2014 | An Integrated Tabletop Platform for Rapid Detection of XDR-TB in Clinical Samples1R01AI111435-01 | RODWELL, TIMOTHY CHARLES | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,364,708 | ZAI1 |
| 2014 | Advancing a Novel Pangenotypic Inhibitor of Human Influenza Virus to an IND1R56AI111460-01 | GLENN, JEFFREY S | STANFORD UNIVERSITY, CA | $1,332,988 | ZAI1 |
| 2014 | An Immunoprotectant for Argentine Hemorrhagic Fever1R01AI111391-01 | ZEITLIN, LARRY | MAPP BIOPHARMACEUTICAL, INC., CA | $1,204,507 | ZAI1 |
| 2014 | Point-of-care Diagnosis and Surveillance of Known and Emerging Influenza Viruses1R01AI111303-01 | GERDES, JOHN CHARLESROSE, TIMOTHY M | SEATTLE CHILDREN'S HOSPITAL, WA | $1,186,565 | ZAI1 |
| 2014 | A Novel Live Non-replicating Universal Vaccine for Influenza1R01AI111451-01 | SARAWAR, SALLY R. | BIOMEDICAL RESEARCH INSTIT/ SOUTHERN, CA, CA | $1,009,220 | ZAI1 |
| 2014 | Surface-enhanced Raman Spectroscopy Immunoassay for Detection of Category A Patho1R01AI111495-01 | PORTER, MARC D | UNIVERSITY OF UTAH, UT | $918,238 | ZAI1 |
| 2014 | Targeting MMP9 to Improve Outcomes in Serious Influenza Infections1R01AI111475-01 | HARROD, KEVIN SOWEN, CAROLINE A | LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE, NM | $852,665 | ZAI1 |
| 2014 | Adjuvants for Skin Immunization: Discovery and Mechanisms1R01AI111557-01 | SKOUNTZOU, IOANNA | EMORY UNIVERSITY, GA | $794,321 | ZAI1 |
| 2014 | Characterization and Development of a Cross Spectrum Anti-Dengue Antibody1R01AI111395-01 | SASISEKHARAN, RAM | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $750,000 | ZAI1 |
| 2014 | Single Dose, Multivalent, Anthrax Plague Vaccines using Bacteriophage T4 Nanopart1R01AI111538-01 | RAO, VENIGALLA B. | CATHOLIC UNIVERSITY OF AMERICA, DC | $693,061 | ZAI1 |
| 2014 | Development of Aminospectinomycins for Biodefense1R01AI111449-01 | LEE, RICHARD E. | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $691,964 | ZAI1 |
| 2014 | Integrated Cost-Effective Point of Care Nucleic Acid Testing for TB diagnosis1R01AI111477-01 | CANGELOSI, GERARD ADOEBLER, ROBERT WILLIAMJONES, BRENDA ELAINENARITA, MASANIEMZ, ANGELIKA | KECK GRADUATE INST OF APPLIED LIFE SCIS, CA | $607,711 | ZAI1 |
| 2014 | Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus1R01AI111516-01 | DYE, JOHN M | GENEVA FOUNDATION, WA | $602,743 | ZAI1 |
| 2014 | Detection of Biodefense Pathogens Using Phage Diagnostics1R01AI111535-01 | SCHOFIELD, DAVID A | GUILD ASSOCIATES, INC., OH | $472,829 | ZAI1 |
| 2014 | Broad-Range VLP Vaccine Against H5N1 Influenza1R01AI111532-01 | PUSHKO, PETER M. | MEDIGEN, INC., MD | $350,000 | ZAI1 |
| 2014 | Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens1R01AI111466-01 | NARASIMHAN, BALAJI | IOWA STATE UNIVERSITY, IA | $349,999 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.